Anondita Medicare Limited · NSE:ANONDITA
Anondita Medicare — Bharat Connect Conference - Rising Stars 2026
35 slides from Anondita Medicare's conference presentation, Mar 7, 2026
Slide 1: Regulation 30 submission letter to NSE
March 07, 2026 To, The Manager, Listing Compliance Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai-400051 Subject: Submission of Investor Presentation for the Arihant Capital “Bharat Connect Conference- Rising Stars 2026” Ref.: SEBI Mas
Slide 2: Investor Presentation
(Formerly known as Anondita Healthcare) Investor Presentation aaa ee
Slide 3: Safe Harbour Statement
Safe Harbour Statement This presentation and its accompanying materials (collectively, the "Presentation") have been prepared by Anondita Medicare Limited ("Anondita," "the Company," or "we") for informational and discussion purposes only. This Presentation does not constitute an offer to sell or so
Slide 4: About Anondita Medicare Limited
About Anondita Medicare Limited Anondita Medicare Limited, is an Indian manufacturer of male and female condoms, operating under its flagship brand “COBRA.” The company runs its own manufacturing facility and follows a quality-driven, compliant production model. The company is led by Mr. Anupam Ghos
Slide 5: Mission & Vision
Mission & Vision MISSION ROADMAP VISION 2026 Addition of manufacturing facilities for female latex condoms. Anondita Medicare Ltd. aspires to be a leading force in the fight against HIV/AIDS and the 2027 Commencement of female latex condom manufacturing. prevention of unintended pregnancies by deliv
Slide 6: Key Facts & Figures
Key Facts & Figures 30+ 11 81+ FY25 Years of Experience Manufacturing lines No. of Machinery Revenue – 7,699.07 EBITDA – 2,565.22 PAT – 1,650.47 4 280+ H1 FY26 Installed New lines Team Size Revenue – 5409.70 EBITDA – 1920.14 PAT – 1301.78 Quality Assurance • Stringent quality control processes • Eac
Slide 7: Key Events And Milestones
Key Events And Milestones 1999 2019 2011-2015 • Got mentioned In various articles in • The erstwhile proprietorship “M/s newspapers, newsletters, etc., and Health Care Products” was started awards as a leading manufacturer of by our current promoter, • Got our factory approved by KFW condoms and sur
Slide 8: Establishment of the Brand “Cobra Condoms”
Establishment of the Brand “Cobra Condoms” After years of supplying our products to top pharmaceutical companies, we have now entered the market with our subsidiary’s brand - Cobra Condoms. Key Highlights Each and every condom is 100% electronically tested Eye-catching designs and visuals Export-qua
Slide 9: Types of Condoms
Types of Condoms Extra Large Ultra-Thin Dotted Multi-textured 01 Condoms 02 Condoms 03 Condoms 04 Condoms Extra Strong Plain Ribbed Female 05 Condoms 06 Condoms 07 Condoms 08 Condoms Exciting Flavors 01 Strawberry 02 Mint 03 Chocolate 04 Butterscotch 05 Coffee 06 Bubblegum Investor Presentation 8
Slide 10: Manufacturing Facility
Manufacturing Facility Enabling operational scale-up and future growth Condoms Production Capacity Noida, Uttar Pradesh Installed Capacity Utilization Capacity Utilization Capacity (%) Location ~9,290 Sq. Mt. Total built-up area 6,0 00.00 50. 00% 5,620.00 5,620.00 5,620.00 46.05% 45. 00% 5,620 lakhs
Slide 11: Scaling Manufacturing Capabilities – Noida Facility
Scaling Manufacturing Capabilities – Noida Facility Approved ~1,360 million pieces per annum capacity expansion at the upcoming Noida manufacturing facility (additional unit) Current vs Expanded Capacity • Existing installed capacity: 869 million pieces per annum, 16 Manufacturing lines under WIP •
Slide 12: Receives SABS Certification for Male Condoms
Receives SABS Certification for Male Condoms • Received SABS certification for natural rubber latex male condoms • Certification as per SANS 4074:2017 standards • Applies to select COBRA brand variants Strategic Significance • Enables access to regulated export markets • South Africa • Africa-focuse
Slide 13: MDSAP Certification Received Under ISO 13485:2016
MDSAP Certification Received Under ISO 13485:2016 Scope of Certification Covers male and female condoms Enables marketing across five regulated international jurisdictions: Australia Brazil Canada Japan United States of America Strategic Importance Provides access to highly regulated medical device
Slide 14: Certifications
Certifications Investor Presentation 13
Slide 15: Management Overview
Management Overview Mr. Anupam Ghosh Mrs. Sonia Ghosh Mr. Reshant Ghosh Managing Director & Promoter Promoter Whole Time Director & Promoter With over 25 years of experience in the Mrs. Ghosh has over 10 years of experience in Mr. Ghosh brings 3 years of experience in marketing healthcare products i
Slide 16: Growth Priorities: Global Expansion, UN Qualification, Automation
Establishment of the Brand “Cobra Condoms” 1 Global Expansion Scale exports beyond Africa into high- potential international markets. 2 UN qualification In advanced stages, enabling access to global markets, with exports targeted to begin by end- FY26 or early next Q1FY26. 3 4 1 2 3 4 Automation & E
Slide 17: SWOT Analysis
SWOT Analysis Strengths Weaknesses S W Established condom manufacturer in India with own Dependence on latex raw material supply, exposing the brand and manufacturing facility. business to procurement and price volatility. Strong demand driven by rising STD awareness and Advantage as one of the few
Slide 18: Global Condom Market Outlook
Global Condom Market Outlook Global Condom Market In USD Billion Global Procurement & Donor Market (Volumes) 17.57 8.10% CAGR 11.9 UNFPA: ~680+ million male condoms + ~6 million female condoms Total global annually across Africa, Asia & institutional LATAM. distribution: ~1.5–2.0 billion condoms per
Slide 19: Indian Condom Market Outlook
Indian Condom Market Outlook India Condom Market Indian Condom Market Segmentation USD Million 773.82 35% 30% 25% 7.45 CAGR 20% 406.31 15% 30% 25% 10% 22% 23% 5% 0% East India North India West & Central India South India FY24 FY33 Based on Product Type: • Male condoms dominate the Indian market with
Slide 20: Demand Drivers
Demand Drivers Large youth population & Urbanisation, rising disposable demographic dividend incomes and premiumisation India has the world’s largest youth cohort (15–29 years ~370–420M) and more consumers in urban / tier-2/3 cities willing to pay for a low median age (~29). A large sexually active
Slide 21: Financial Snapshot (Consolidated)
Financial Snapshot (Consolidated) (Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Revenue from Operations EBITDA EBITDA Margin PAT PAT Margin EPS 30. 00% 140 0.00 1301.78 36. 00% 250 0.00 5,410 35.49% 9.12 120 0.00 35. 00%
Slide 22: Income Statement (Half Yearly) Consolidated
Income Statement (Half Yearly) Consolidated (Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Particulars H1 FY26 H1 FY25 YoY Change Revenue from operations 5,409.70 3,140.50 72% Cost of Material Consumed 2,438.97 1,611.11 E
Slide 23: Balance sheet (Half Yearly) Consolidated
Balance sheet (Half Yearly) Consolidated (Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Equities and Liabilities H1 FY26 H1 FY25 Assets H1 FY26 H1 FY24 Shareholder's Funds Non-current Assets Share Capital 1,808.79 886.36
Slide 24: Cashflow Statement (Half Yearly) Consolidated
Cashflow Statement (Half Yearly) Consolidated (Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Cash Flow Statement (in ₹ Lakh) H1 FY26 H1 FY25 Cash Flow from Operating Activity -1,171.09 -1,589.45 Cash Flow from Investing A
Slide 25: Financial Snapshot (Standalone)
Financial Snapshot (Standalone) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Revenue from Operations EBITDA EBITDA Margin PAT PAT Margin EPS 30. 00% 140 0.00 40. 00% 180 0.00 1678.51 8.14 25. 00% 1146.57 120 0.00 35. 00% 35.23% 160 0.00 24.06% 4,765.06 100 0.00 140 0.00 30. 00% 20. 00% 120 0.00 800 .00
Slide 26: Income Statement (Half Yearly) Standalone
Income Statement (Half Yearly) Standalone In ₹ Lakhs Particulars H1 FY26 H1 FY25 YoY Change Revenue from operations 4765.06 2497.06 91% Cost of Material Consumed 2166.28 1486.25 Employee benefit expense 271.06 223.68 Other Expenses 649.21 256.15 Total 3086.55 1966.08 EBITDA 1678.51 530.98 216% EBITD
Slide 27: Balance Sheet (Half Yearly) Standalone
Balance Sheet (Half Yearly) Standalone In ₹ Lakhs Equities and Liabilities H1 FY26 H1 FY25 Assets H1 FY26 H1 FY24 Shareholder's Funds Non-current Assets Share Capital 1,808.66 886.24 Fixed Assets 1,275.48 1,246.15 Reserves & Surplus 7,963.81 1,077.21 Goodwill Minority Interest Capital Work in progre
Slide 28: Cashflow Statement (Half Yearly) Standalone
Cashflow Statement (Half Yearly) Standalone In ₹ Lakhs Cash Flow Statement (in ₹ Lakh) H1 FY26 H1 FY25 Cash Flow from Operating Activity (1,253.13) (1,124.92) Cash Flow from Investing Activity (945.60) (1,683.18) Cash Flow from Financing Activity 5,801.45 2,846.92 Cash and Cash Equivalents at the Be
Slide 29: Historical Income Statement
Historical Income Statement In ₹ Lakhs Anondita Medicare Ltd Anondita Medicare Ltd. Anondita Healthcare (Consolidated ) (Standalone) (Proprietorship) Particulars FY25 FY25 FY24 FY23 (A) REVENUE Revenue from Operations 7,699.07 6051.52 4,643.21 3,591.49 Other Income 13.88 36.38 12.33 22.48 Total Reve
Slide 30: Historical Balance Sheet
Historical Balance Sheet In ₹ Lakhs Anondita Medicare Ltd Anondita Medicare Ltd. Anondita Healthcare (Consolidated ) (Standalone) (Proprietorship) Particulars FY25 FY25 FY24 FY23 (A) EQUITY AND LIABILITIES 1. Shareholders’ Funds (a) Share Capital 1,329.36 1,329.36 – – (b) Proprietor’s Capital Balanc
Slide 31: Historical Balance Sheet
Historical Balance Sheet In ₹ Lakhs Anondita Medicare Ltd Anondita Medicare Ltd. Anondita Healthcare (Consolidated ) (Standalone) (Proprietorship) Particulars FY25 FY25 FY24 FY23 B. ASSETS 1. Non-Current Assets (a) Property, Plant & Equipment and Intangible Assets (i) Property, Plant & Equipment 1,3
Slide 32: Historical Cashflow Statement
Historical Cashflow Statement In ₹ Lakhs Anondita Medicare Ltd Anondita Medicare Ltd. Anondita Healthcare (Consolidated ) (Standalone) (Proprietorship) Cash Flow Statement (in ₹ Lakh) FY25 FY25 FY24 FY23 Cash Flow from Operating Activity -1046.59 607.96 1054.88 -949.63 Cash Flow from Investing Activ
Slide 33: Strategy Going Forward
Strategy Going Forward Expanding Global Reach UN Qualification and • Anondita Medicare Ltd. has obtained the SABS licence from the South African Bureau of Standards, confirming Export Launch compliance with national and international quality, • The Company is applying for UNFPA Pre- safety, and perf
Slide 34: Goal for FY26
Goal for FY26 Increase production Develop innovative Implement sustainable Launch community capacity contraceptives practices education programs Export to Brazil and South To increase our market share American countries in condom industry Expand distribution Develop robust quality Advocate for polic
Slide 35: THANK YOU
THANK YOU
Anondita Medicare — Bharat Connect Conference - Rising Stars 2026 on 6ix